SELLAS Life Sciences Group, Inc. - SLS Net earnings per one share for the last twelve months
This price evolution chart on GURU.Markets for SELLAS Life Sciences (SLS) shows an EPS of 35.70. The survival of this immunotherapy developer currently depends on the results of final leukemia tests amid nearly depleted capital. Business success relies on the efficacy of acute myeloid leukemia treatment and access to funding. Growth is driven by orphan drug privileges and the trial results of the galinpepimut-S vaccine.
SLS (SELLAS Life Sciences Group Inc.): analytical breakdowns and indicator data
- current price and projected stock value:
- issuer market value details:
- company book value details:
- debt and liquidity data:
Debt to Equity SELLAS Life Sciences|SLS - Long-Term Debt to Equity|Short-Term Debt to Equity SELLAS Life Sciences|SLS - Company Aggregate Debts|Debts to Book Capitalization SELLAS Life Sciences Group, Inc.|SLS - Company Long-Term Debt|Short-Term Debt Volume SELLAS Life Sciences|Intermediate Coverage Ratio sellaslifesciences.com
- business earnings and investment ratios data:
SLS - Company Net Income|Expected Profit SELLAS Life Sciences|SLS - P/E Multiple|Market Cap to Projected Earnings SELLAS Life Sciences|SLS - PEG Multiple|Company Value to Operating Income Before Depreciation Ratio SELLAS Life Sciences Group, Inc.|SLS - Operating profit EBITDA|Net earnings per one share for the last twelve months SELLAS Life Sciences|SLS - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months sellaslifesciences.com|SLS - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year SELLAS Life Sciences
- sales and revenue indicators:
Fundamental company valuation:SLS - SELLAS Life Sciences Group
The market views SELLAS Life Sciences (SLS) as a high-risk asset with breakthrough potential in leukemia therapy. This metric measures the dynamics of net income per share over a trailing twelve-month period, allowing for a real-time assessment of the business's profitability trends. By analyzing the annual percentage change in earnings per share (TTM), investors can see the impact of vaccine costs on capitalization. For the biotech sector, this indicator serves as a marker of financial stability amidst a constant search for investment.
Competitor analysis
Earnings per share for the trailing year ONC (beigene.com)|HALO: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Revolution Medicines Inc (RVMD)|Earnings per share for the last twelve months Ascentage|CG Oncology Therapeutics (CGON) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) URGN|BCAX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Personalis PSNL|Erasca Inc - Earnings per share for the last twelve months|DCTH - Earnings per share for the last twelve months|YMAB: Earnings per share for the last twelve months|AURA: Net earnings per share (EPS TTM)|Candel Therapeutics, Inc. (CADL) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Accuray|Actuate Therapeutics Inc. (ACTU) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months CTOR (Citius Oncology, Inc)|HURA (tuhurabio.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Protara Therapeutics TARA|fatetherapeutics.com - Earnings per share for the last twelve months|Aadi Bio - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters TScan Therapeutics TCRX|CSBR: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months XBIT (XBiotech)|CVM (CEL-SCI Corp.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ostherapies.com OSTX|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|ARTV (artivabio.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Adlai Nortye ANL|Net earnings per share for the last four quarters Veru Corporation (VERU)|Tempest Therapeutics - Net earnings per share (EPS TTM)|Xilio Therapeutics, Inc. (XLO) - Net earnings per share for the last 12 months|RENB: Net earnings per share (EPS TTM)|MURA - Net earnings per share for the last four quarters|KAPA (Kairos Pharma Limited) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months OnKure OKUR|Earnings per share for the last twelve months CytoMed Therapeutics (GDTC)|curis.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) APLM (Apollomics)|THAR - Net earnings per share for the last 12 months|Advanced Biomed Corp - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Genprex Inc|calidibio.com (CLDI) - Earnings per share for the last twelve months|SBFM - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Xenetic Biosciences Inc.|Salarius Pharmaceuticals Inc (SLRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Purple Biotech Corp (PPBT)|Earnings per share for the last twelve months AONC (aoncology.com)|Earnings per share for the last twelve months BeiGene, Ltd. BGNE|Net earnings per share for the last four quarters checkpointtx.com (CKPT)|Elevation Oncology, Inc. - Net earnings per share (EPS TTM)|iCAD, Inc. (ICAD) - Net earnings per share for the last 12 months|IKNA: Net earnings per share (EPS TTM)|Notable Labs Corp (NTBL) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Viracta Therapeutics Inc.|Earnings per share for the last 12 months MOR (morphosys.com)|Net earnings per share (EPS TTM) NAYA|Net earnings per share for the last 12 months Ascentage Pharma Group International AAPGV
